| (1S)-CCR2 antagonist 1 |
|
|
|
|
|
|
|
|
|
98.03% |
| (Rac)-PF-4136309 |
|
|
|
|
|
|
|
|
|
|
| (S)-IDOR-1117-2520 |
|
|
|
|
|
|
|
|
|
99.47% |
| (s)-PF-4136309 |
|
|
|
|
|
|
|
|
|
98.93% |
| 7,4'-Dihydroxyflavone |
|
|
|
|
|
|
|
|
|
99.64% |
| Abaucin |
|
|
|
|
|
|
|
|
|
99.59% |
| Abaucin hydrochloride |
|
|
|
|
|
|
|
|
|
99.94% |
| ABT-182 |
|
|
|
|
|
|
|
|
|
|
| ALK4290 |
|
|
|
|
|
|
|
|
|
99.79% |
| ALK4290 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
| Ancriviroc |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL2 (Carlumab)-MC-Vc-PAB-SN38 |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL2 (Carlumab)-McMMAF |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL2 (Carlumab)-SMCC-DM1 |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL2 (Carlumab)-SPDB-DM4 |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL2 (Carlumab)-VcMMAE |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL21 Antibody |
|
|
|
|
|
|
|
|
|
|
| Anti-CCL28 Antibody |
|
|
|
|
|
|
|
|
|
|
| Anti-CCR1 Antibody |
|
|
|
|
|
|
|
|
|
|
| Anti-CCR5 Antibody (HEK/1/85a/7a) |
|
|
|
|
|
|
|
|
|
|
| Anti-CCR6 Antibody |
|
|
|
|
|
|
|
|
|
|
| Anti-CCR9 Antibody |
|
|
|
|
|
|
|
|
|
|
| Anti-inflammatory agent 87 |
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CCR2 Antibody (C2Mab-6) |
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CCR3/CD193 Antibody (6S2-19-4) |
|
|
|
|
|
|
|
|
|
99.13% |
| Anti-Mouse CCR5 Antibody (C5Mab-2) |
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse CCR8 Antibody (C8Mab-2) |
|
|
|
|
|
|
|
|
|
|
| Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) |
|
|
|
|
|
|
|
|
|
99.5% |
| Aplaviroc |
|
|
|
|
|
|
|
|
|
|
| Aplaviroc hydrochloride |
|
|
|
|
|
|
|
|
|
99.94% |
| AT008 |
|
|
|
|
|
|
|
|
|
|
| AZ084 |
|
|
|
|
|
|
|
|
|
99.70% |
| AZ760 |
|
|
|
|
|
|
|
|
|
|
| AZD-1678 |
|
|
|
|
|
|
|
|
|
98.65% |
| AZD-4818 |
|
|
|
|
|
|
|
|
|
99.10% |
| AZD-5672 |
|
|
|
|
|
|
|
|
|
95.74% |
| AZD2098 |
|
|
|
|
|
|
|
|
|
99.91% |
| AZD2423 |
|
|
|
|
|
|
|
|
|
99.91% |
| AZD3778 |
|
|
|
|
|
|
|
|
|
|
| Azirkitug |
|
|
|
|
|
|
|
|
|
98% |
| BAY-3153 |
|
|
|
|
|
|
|
|
|
|
| BI 639667 |
|
|
|
|
|
|
|
|
|
98.87% |
| BI-6901 |
|
|
|
|
|
|
|
|
|
99.94% |
| BMS CCR2 22 |
|
|
|
|
|
|
|
|
|
99.27% |
| BMS-457 |
|
|
|
|
|
|
|
|
|
|
| BMS-570520 |
|
|
|
|
|
|
|
|
|
|
| BMS-639623 |
|
|
|
|
|
|
|
|
|
|
| BMS-681 |
|
|
|
|
|
|
|
|
|
|
| BMS-741672 |
|
|
|
|
|
|
|
|
|
|
| BMS-753426 |
|
|
|
|
|
|
|
|
|
|
| BMS-813160 |
|
|
|
|
|
|
|
|
|
99.93% |
| BMS-817399 |
|
|
|
|
|
|
|
|
|
99.66% |
| BX-513 |
|
|
|
|
|
|
|
|
|
|
| BX471 |
|
|
|
|
|
|
|
|
|
99.98% |
| BX471 hydrochloride |
|
|
|
|
|
|
|
|
|
99.94% |
| C-021 |
|
|
|
|
|
|
|
|
|
99.95% |
| C-021 dihydrochloride |
|
|
|
|
|
|
|
|
|
99.73% |
| Cafelkibart |
|
|
|
|
|
|
|
|
|
99% |
| Calamenene |
|
|
|
|
|
|
|
|
|
|
| CAP-100 |
|
|
|
|
|
|
|
|
|
99.84% |
| Catenarin |
|
|
|
|
|
|
|
|
|
|
| CB-0821 |
|
|
|
|
|
|
|
|
|
|
| CCL17-IN-1 |
|
|
|
|
|
|
|
|
|
|
| CCL17-IN-2 |
|
|
|
|
|
|
|
|
|
|
| CCR1 antagonist 10 |
|
|
|
|
|
|
|
|
|
|
| CCR1 antagonist 11 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| CCR1 antagonist 12 |
|
|
|
|
|
|
|
|
|
|
| CCR1 antagonist 13 |
|
|
|
|
|
|
|
|
|
|
| CCR1 antagonist 6 |
|
|
|
|
|
|
|
|
|
|
| CCR1 antagonist 7 |
|
|
|
|
|
|
|
|
|
|
| CCR1 antagonist 9 |
|
|
|
|
|
|
|
|
|
99.65% |
| CCR1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| Ccr1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR2 antagonist 1 |
|
|
|
|
|
|
|
|
|
95.04% |
| CCR2 antagonist 3 |
|
|
|
|
|
|
|
|
|
99.91% |
| CCR2 antagonist 4 |
|
|
|
|
|
|
|
|
|
100.0% |
| CCR2 antagonist 4 hydrochloride |
|
|
|
|
|
|
|
|
|
99.91% |
| CCR2 antagonist 6 |
|
|
|
|
|
|
|
|
|
|
| CCR2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR2 ligand-1 |
|
|
|
|
|
|
|
|
|
|
| Ccr2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| Ccr2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR2-IN-1 |
|
|
|
|
|
|
|
|
|
|
| CCR2-RA |
|
|
|
|
|
|
|
|
|
|
| CCR2-RA-[R] |
|
|
|
|
|
|
|
|
|
99.21% |
| CCR3 antagonist 1 |
|
|
|
|
|
|
|
|
|
99.90% |
| CCR3 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
| CCR3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| Ccr3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| Ccr3 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR4 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
| CCR4 antagonist 3-1 |
|
|
|
|
|
|
|
|
|
99.94% |
| CCR4 antagonist 4 |
|
|
|
|
|
|
|
|
|
98.92% |
| CCR4 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| Ccr4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR4-351 |
|
|
|
|
|
|
|
|
|
98.95% |
| CCR4-351 hydrochloride |
|
|
|
|
|
|
|
|
|
98.14% |
| CCR5 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
| CCR5 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
| CCR5 antagonist 3 |
|
|
|
|
|
|
|
|
|
|
| CCR5 antagonist 4 |
|
|
|
|
|
|
|
|
|
|
| CCR5 antagonist 5 |
|
|
|
|
|
|
|
|
|
|
| CCR5 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR5 modulator-1 |
|
|
|
|
|
|
|
|
|
|
| CCR5-IN-1 |
|
|
|
|
|
|
|
|
|
|
| CCR5/CXCR3-IN-1 |
|
|
|
|
|
|
|
|
|
|
| CCR6 antagonist 1 |
|
|
|
|
|
|
|
|
|
99.30% |
| CCR6 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
| CCR6 antagonist 3 |
|
|
|
|
|
|
|
|
|
|
| CCR6 antagonist 4 |
|
|
|
|
|
|
|
|
|
|
| CCR6 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR6 inhibitor 1 |
|
|
|
|
|
|
|
|
|
99.60% |
| Ccr6 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR7 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR7 Ligand 1 |
|
|
|
|
|
|
|
|
|
99.19% |
| Ccr7 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR8 antagonist 1 |
|
|
|
|
|
|
|
|
|
99.50% |
| CCR8 antagonist 3 |
|
|
|
|
|
|
|
|
|
|
| CCR8 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| Ccr8 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR9 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCR9 ligand-Linker Conjugate 1 |
|
|
|
|
|
|
|
|
|
|
| CCR9 modulator-1 |
|
|
|
|
|
|
|
|
|
|
| Ccr9 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
| CCX354 |
|
|
|
|
|
|
|
|
|
99.18% |
| Cenicriviroc |
|
|
|
|
|
|
|
|
|
99.51% |
| Cenicriviroc Mesylate |
|
|
|
|
|
|
|
|
|
99.94% |
| CH0076989 |
|
|
|
|
|
|
|
|
|
|
| cis-INCB3344 |
|
|
|
|
|
|
|
|
|
95.10% |
| cis-J-113863 |
|
|
|
|
|
|
|
|
|
|
| CKLF1-C19 |
|
|
|
|
|
|
|
|
|
99.11% |
| CKLF1-C27 |
|
|
|
|
|
|
|
|
|
98.02% |
| CKLF1-C27 TFA |
|
|
|
|
|
|
|
|
|
|
| CM369 |
|
|
|
|
|
|
|
|
|
|
| CMKLR1 antagonist 1 |
|
|
|
|
|
|
|
|
|
99.70% |
| CMKLR1 antagonist 2 |
|
|
|
|
|
|
|
|
|
|
| CMPD167 |
|
|
|
|
|
|
|
|
|
|
| Cosalane |
|
|
|
|
|
|
|
|
|
99.50% |
| CP-481715 |
|
|
|
|
|
|
|
|
|
|
| CP-865569 |
|
|
|
|
|
|
|
|
|
|
| CXCR2 antagonist 10 |
|
|
|
|
|
|
|
|
|
|
| CXCR2/CCR7 antagonist-1 |
|
|
|
|
|
|
|
|
|
|
| DAPTA |
|
|
|
|
|
|
|
|
|
99.40% |
| DCLL9718A Antibody |
|
|
|
|
|
|
|
|
|
|
| Denikitug |
|
|
|
|
|
|
|
|
|
99.00% |
| Denrakibart |
|
|
|
|
|
|
|
|
|
98.24% |
| Dicytidine 5′-triphosphate |
|
|
|
|
|
|
|
|
|
|
| Dicytidine 5′-triphosphate trisodium |
|
|
|
|
|
|
|
|
|
|
| DOTA-ECL1i |
|
|
|
|
|
|
|
|
|
98.06% |
| DPC-168 |
|
|
|
|
|
|
|
|
|
|
| E913 |
|
|
|
|
|
|
|
|
|
|
| ECL1i |
|
|
|
|
|
|
|
|
|
|
| ECL1i TFA |
|
|
|
|
|
|
|
|
|
|
| Emapticap pegol |
|
|
|
|
|
|
|
|
|
91.38% |
| Emapticap pegol scramble negative control |
|
|
|
|
|
|
|
|
|
|
| Emapticap pegol sodium |
|
|
|
|
|
|
|
|
|
91.38% |
| Enzelkitug (FUT8-KO) |
|
|
|
|
|
|
|
|
|
|
| Flt-3L-Ig (hum/hum) |
|
|
|
|
|
|
|
|
|
98% |
| Fuscin |
|
|
|
|
|
|
|
|
|
|
| Globulol |
|
|
|
|
|
|
|
|
|
99.74% |
| GSK-214096 |
|
|
|
|
|
|
|
|
|
|
| GSK-2239633 |
|
|
|
|
|
|
|
|
|
|
| GSK-3050002 |
|
|
|
|
|
|
|
|
|
97.30% |
| GSK163929 |
|
|
|
|
|
|
|
|
|
|
| GSK2239633A |
|
|
|
|
|
|
|
|
|
99.81% |
| GW 766994 |
|
|
|
|
|
|
|
|
|
98.73% |
| GW 766994 (Standard) |
|
|
|
|
|
|
|
|
|
|
| HFB101110 |
|
|
|
|
|
|
|
|
|
|
| HGS004 |
|
|
|
|
|
|
|
|
|
|
| HGS101 |
|
|
|
|
|
|
|
|
|
|
| Histamine glutarimide |
|
|
|
|
|
|
|
|
|
|
| HZ-1127 |
|
|
|
|
|
|
|
|
|
|
| IBS007125 |
|
|
|
|
|
|
|
|
|
|
| IDOR-1117-2520 |
|
|
|
|
|
|
|
|
|
99.94% |
| Ilacirnon |
|
|
|
|
|
|
|
|
|
98.05% |
| INCB 3284 |
|
|
|
|
|
|
|
|
|
99.30% |
| INCB 3284 dimesylate |
|
|
|
|
|
|
|
|
|
|
| INCB3344 |
|
|
|
|
|
|
|
|
|
99.81% |
| INCB3344 R-isomer |
|
|
|
|
|
|
|
|
|
98.01% |
| INCB9471 |
|
|
|
|
|
|
|
|
|
|
| J-113863 |
|
|
|
|
|
|
|
|
|
95.19% |
| JBH492 Antibody |
|
|
|
|
|
|
|
|
|
|
| JNJ-17166864 |
|
|
|
|
|
|
|
|
|
|
| JNJ-27141491 |
|
|
|
|
|
|
|
|
|
97.01% |
| JNJ-41443532 |
|
|
|
|
|
|
|
|
|
99.65% |
| Lanerkitug |
|
|
|
|
|
|
|
|
|
97.00% |
| Lanerkitug (FUT8-KO) |
|
|
|
|
|
|
|
|
|
99.27% |
| LMD-009 |
|
|
|
|
|
|
|
|
|
99.35% |
| LMD-584 |
|
|
|
|
|
|
|
|
|
|
| LMD-902 |
|
|
|
|
|
|
|
|
|
|
| LT166 |
|
|
|
|
|
|
|
|
|
|
| LUF7996 |
|
|
|
|
|
|
|
|
|
|
| LUF8100 |
|
|
|
|
|
|
|
|
|
98.64% |
| Maceneolignan H |
|
|
|
|
|
|
|
|
|
|
| Maraviroc-d6 |
|
|
|
|
|
|
|
|
|
|
| Met-RANTES (human) |
|
|
|
|
|
|
|
|
|
|
| Met-RANTES (human) acetate |
|
|
|
|
|
|
|
|
|
99.39% |
| Minokitug |
|
|
|
|
|
|
|
|
|
99.25% |
| MK-0812 |
|
|
|
|
|
|
|
|
|
99.89% |
| MK-0812 Succinate |
|
|
|
|
|
|
|
|
|
99.94% |
| ML604086 |
|
|
|
|
|
|
|
|
|
99.78% |
| MLN3126 |
|
|
|
|
|
|
|
|
|
98.02% |
| mNOX-E36 |
|
|
|
|
|
|
|
|
|
|
| MOG(35-55) amide, mouse, rat |
|
|
|
|
|
|
|
|
|
99.88% |
| MR2938 |
|
|
|
|
|
|
|
|
|
|
| Nebokitug |
|
|
|
|
|
|
|
|
|
98.80% |
| ON203 |
|
|
|
|
|
|
|
|
|
|
| Ophiobolin C |
|
|
|
|
|
|
|
|
|
|
| PF-04634817 |
|
|
|
|
|
|
|
|
|
|
| PF-04634817 succinate |
|
|
|
|
|
|
|
|
|
99.50% |
| PF-07054894 |
|
|
|
|
|
|
|
|
|
99.15% |
| PF-232798 |
|
|
|
|
|
|
|
|
|
|
| PF-4136309 |
|
|
|
|
|
|
|
|
|
99.86% |
| PF-4178903 |
|
|
|
|
|
|
|
|
|
|
| PLS-123 |
|
|
|
|
|
|
|
|
|
|
| PNU-177864 |
|
|
|
|
|
|
|
|
|
|
| PNU-177864 hydrochloride |
|
|
|
|
|
|
|
|
|
|
| Procurcumenol |
|
|
|
|
|
|
|
|
|
|
| Propagermanium |
|
|
|
|
|
|
|
|
|
|
| PROTAC CCR9 Degrader 1 |
|
|
|
|
|
|
|
|
|
|
| PROTAC IRAK4 degrader-14 |
|
|
|
|
|
|
|
|
|
|
| R243 |
|
|
|
|
|
|
|
|
|
98.09% |
| R707 |
|
|
|
|
|
|
|
|
|
|
| RAGE406R |
|
|
|
|
|
|
|
|
|
|
| RAP-103 |
|
|
|
|
|
|
|
|
|
|
| Resolvin D5 |
|
|
|
|
|
|
|
|
|
98.3% |
| RO5234444 |
|
|
|
|
|
|
|
|
|
|
| RP23618 |
|
|
|
|
|
|
|
|
|
|
| RS 504393 |
|
|
|
|
|
|
|
|
|
99.72% |
| S-531011 |
|
|
|
|
|
|
|
|
|
98.38% |
| S-531011 (FUT8-KO) |
|
|
|
|
|
|
|
|
|
99.10% |
| SB-328437 |
|
|
|
|
|
|
|
|
|
99.58% |
| SB-649701 |
|
|
|
|
|
|
|
|
|
|
| SB297006 |
|
|
|
|
|
|
|
|
|
99.86% |
| SCH 350581 |
|
|
|
|
|
|
|
|
|
|
| SLW131 |
|
|
|
|
|
|
|
|
|
|
| SQA1 |
|
|
|
|
|
|
|
|
|
|
| ST45177901 |
|
|
|
|
|
|
|
|
|
|
| Tagmokitug |
|
|
|
|
|
|
|
|
|
99.9% |
| TAK-220 |
|
|
|
|
|
|
|
|
|
99.94% |
| TAK-661 |
|
|
|
|
|
|
|
|
|
|
| TAK-779 |
|
|
|
|
|
|
|
|
|
99.89% |
| Tanimilast |
|
|
|
|
|
|
|
|
|
99.71% |
| TAVO101 |
|
|
|
|
|
|
|
|
|
|
| TBK1 degrader-4 |
|
|
|
|
|
|
|
|
|
|
| Tivumecirnon |
|
|
|
|
|
|
|
|
|
99.48% |
| trans-J-113863 |
|
|
|
|
|
|
|
|
|
|
| TSLP modulator-1 |
|
|
|
|
|
|
|
|
|
99.61% |
| Val-Gly-Ser-Glu |
|
|
|
|
|
|
|
|
|
|
| VCH-286 |
|
|
|
|
|
|
|
|
|
|
| Velaprumig |
|
|
|
|
|
|
|
|
|
|
| Vicriviroc |
|
|
|
|
|
|
|
|
|
|
| Vicriviroc malate |
|
|
|
|
|
|
|
|
|
|
| Vicriviroc maleate |
|
|
|
|
|
|
|
|
|
98.49% |
| VLST-002 |
|
|
|
|
|
|
|
|
|
|
| YJC-10592 |
|
|
|
|
|
|
|
|
|
|
| YM-344031 |
|
|
|
|
|
|
|
|
|
|
| YM-344484 |
|
|
|
|
|
|
|
|
|
|
| YM022 |
|
|
|
|
|
|
|
|
|
99.87% |
| Zelnecirnon |
|
|
|
|
|
|
|
|
|
99.71% |
| ZK 756326 |
|
|
|
|
|
|
|
|
|
|
| ZK756326 dihydrochloride |
|
|
|
|
|
|
|
|
|
99.87% |
| ZL-1218 |
|
|
|
|
|
|
|
|
|
|
| ZL-1218 (FUT8-KO) |
|
|
|
|
|
|
|
|
|
|
| Zn-DPA-maytansinoid conjugate 1 |
|
|
|
|
|
|
|
|
|
|
| Leronlimab |
|
|
|
|
|
|
|
|
|
98.91% |
| Carlumab |
|
|
|
|
|
|
|
|
|
97.80% |
| Pirfenidone-d5 |
|
|
|
|
|
|
|
|
|
98.88% |
| Pirfenidone |
|
|
|
|
|
|
|
|
|
99.99% |
| Enzelkitug |
|
|
|
|
|
|
|
|
|
|
| Bindarit |
|
|
|
|
|
|
|
|
|
99.51% |
| Nifeviroc |
|
|
|
|
|
|
|
|
|
99.39% |
| Bertilimumab |
|
|
|
|
|
|
|
|
|
97.01% |
| Viscumneoside V |
|
|
|
|
|
|
|
|
|
98.24% |
| Plozalizumab |
|
|
|
|
|
|
|
|
|
99.53% |
| Medrysone |
|
|
|
|
|
|
|
|
|
99.79% |
| Vercirnon |
|
|
|
|
|
|
|
|
|
98.01% |
| Vercirnon sodium |
|
|
|
|
|
|
|
|
|
98.04% |
| Mogamulizumab |
|
|
|
|
|
|
|
|
|
96.9% |
| Maraviroc |
|
|
|
|
|
|
|
|
|
99.98% |